The Natera Inc (NTRA) share price is expected to increase by 14.74% over the next year. This is based on calculating the average 12-month share price estimate provided by 6 stock analysts who have covered NTRA. Price targets range from $70.00 at the low end to $90.00 at the high end. The current analyst consensus for NTRA is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 6 Wall Street analysts have assigned NTRA 6 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Natera Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on NTRA. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
david westenberg Piper Sandler | Buy | $70.0 | rated | Jan 30, 2024 |
puneet souda Leerink Partners | Buy | None | maintained | Jan 29, 2024 |
matthew sykes Goldman Sachs | Buy | $80.0 | maintained | Jan 29, 2024 |
catherine ramsey schulte Robert W. Baird | Buy | $90.0 | maintained | Jan 29, 2024 |
doug schenkel Wolfe Research | Buy | $70.0 | reiterated | Jan 26, 2024 |
alexander nowak Craig-Hallum | Buy | None | rated | Jan 22, 2024 |
mark massaro BTIG | Buy | $85.0 | maintained | Jan 1, 2024 |
daniel brennan TD Cowen | Buy | $87.0 | maintained | Dec 12, 2023 |
andrew cooper Raymond James | Buy | $68.0 | maintained | Nov 13, 2023 |
tejas savant Morgan Stanley | Buy | $68.0 | maintained | Nov 10, 2023 |
kyle mikson cfa Canaccord Genuity | Buy | $87.0 | maintained | Nov 8, 2023 |
eve burstein Bernstein | Hold | $48.0 | initiatedcoverage | Sep 28, 2023 |
rachel vatnsdal J.P. Morgan | Buy | $70.0 | maintained | Aug 4, 2023 |
dan leonard Credit Suisse | Buy | $70.0 | maintained | May 10, 2023 |
tycho peterson J.P. Morgan | Buy | $85.0 | maintained | May 10, 2023 |
julia qin J.P. Morgan | Buy | $85.0 | maintained | May 10, 2023 |
mason carrico Stephens | Buy | None | maintained | Dec 16, 2022 |
navann ty Exane BNP Paribas | Sell | $28.0 | initiatedcoverage | Dec 8, 2022 |
max masucci Cowen & Co. | Buy | $100.0 | maintained | May 6, 2022 |
steven mah Cowen & Co. | Buy | $160.0 | maintained | Aug 9, 2021 |
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company's products also comprise Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.
When did it IPO
2015
Staff Count
2,958
Country
United States
Sector/Industry
Healthcare/Diagnostics & Research
CEO
Mr. Steven Leonard Chapman
Market Cap
$8.41B
In 2023, NTRA generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that NTRA's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
CHRW-USD
$73.65
MKSI-USD
$124.74
LCID-USD
$3.7
MKTX-USD
$219.04
OLED-USD
$181.76
PARA-USD
$12